



- [1] **“Factors Impacting the Performance Characteristics of Bile Duct Brushings: A Clinico-Cytopathologic Analysis of 253 Patients,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [2] **“Liposuction-Induced Fat Embolism Syndrome: A Brief Review and Postmortem Diagnostic Approach,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [3] **“Quantitative Assessment of Immunohistochemistry Laboratory Performance by Measuring Analytic Response Curves and Limits of Detection,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [4] **“Immunohistochemical Expression of p16 in Melanocytic Lesions: An Updated Review and Meta-analysis,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [5] **“Commentary on Testing of Non-Adenocarcinomas,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [6] **“Recent Changes of Classification for Squamous Intraepithelial Lesions of the Head and Neck,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [7] **“Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [8] **“Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [9] **“Performance Characteristics of Cerebrospinal Fluid Cytology: An Analysis of Responses From the College of American Pathologists Nongynecologic Cytopathology Education Program,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [10] **“The 16th Spring Seminar of the Korean Pathologists Association of North America,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [11] **“Immunohistochemistry in Anaplastic Lymphoma Kinase and Proto-Oncogene Tyrosine-Protein Kinase ROS,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [12] **“Molecular Testing for Early Lung Cancer,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [13] **“Molecular Testing for Stage IV Non–Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [14] **“*BRAF* Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [15] **“Single Genes, Panels, and Next-Generation Sequencing Platforms: A Financial Perspective,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [16] **“Cell-Free DNA Utility and Value of Recommendation,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [17] **“Molecular Testing in Lung Cancer: Where to Draw the Line?,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [18] **“Keeping Up With Testing Guidelines in Lung Cancer,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [19] **“Meningothelial-like Nodules of the Lung Show SSTR2a Immunohistochemical Staining,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.
- [20] **“Management of a Hospital Transfusion Service During a Nationwide Blood Product Shortage,”** *Arch. Pathol. Lab. Med.*, Jul. 2018.

Seminars in Diagnostic Pathology

- [1] “Iatrogenic solid tumors following immunosuppressive therapy,” *Semin. Diagn. Pathol.*, Jul. 2018.
- [2] “Drug induced pseudolymphoma,” *Semin. Diagn. Pathol.*, Jul. 2018.
- [3] “Iatrogenic lesions of soft tissue and bone,” *Semin. Diagn. Pathol.*, Jul. 2018.
- [4] “Iatrogenic pulmonary lesions,” *Semin. Diagn. Pathol.*, Jul. 2018.
- [5] “Iatrogenic pathology of the urinary bladder,” *Semin. Diagn. Pathol.*, Jul. 2018.
- [6] “Iatrogenically false positive sentinel lymph nodes in breast cancer: Methods of recognition and evaluation,” *Semin. Diagn. Pathol.*, Jul. 2018.
- [7] “Reexamining post-transplant lymphoproliferative disorders: Newly recognized and enigmatic types,” *Semin. Diagn. Pathol.*, Jul. 2018.



Pas d'édition



- [1] “Primary fallopian tube sex cord tumour: tubal counterpart of uterine tumour resembling ovarian sex cord tumour,” *Histopathology*, Jul. 2018.
- [2] “Immunoglobulin G4-related sclerosing oesophagitis in a 9-year-old girl,” *Histopathology*, Jul. 2018.
- [3] “A monoclonal antibody against SV40 large T antigen (PAb416) does not label Merkel cell carcinoma,” *Histopathology*, Jul. 2018.
- [4] “Erdheim-Chester disease: description of two illustrative cases involving the lung,” *Histopathology*, Jul. 2018.
- [5] “Extraskelletal osteosarcoma: MDM2 and H3K27me3 analysis of 19 cases suggest disease heterogeneity,” *Histopathology*, Jul. 2018.
- [6] “Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system,” *Histopathology*, Jul. 2018.
- [7] “Primary peri-anal adenocarcinoma of intestinal type - a new proposed entity,” *Histopathology*, Jul. 2018.
- [8] “Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma,” *Histopathology*, Jul. 2018.

- [9] “Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease,” *Histopathology*, Jul. 2018.
- [10] “Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers,” *Histopathology*, Jul. 2018.
- [11] “Assessment of HER2 status in breast cancer biopsies is not affected by accelerated tissue processing,” *Histopathology*, Jul. 2018.
- [12] “Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes,” *Histopathology*, Jul. 2018.
- [13] “Hepatic angiomyolipoma: mutation analysis and immunohistochemical pitfalls in diagnosis,” *Histopathology*, Jul. 2018.
- [14] “Basal cell carcinoma induced by therapeutic radiation for tinea capitis-clinicopathological study,” *Histopathology*, Jul. 2018.
- [15] “Grade 4 asbestosis does not extend directly from the respiratory bronchiole to the peripheral lung,” *Histopathology*, Jul. 2018.
- [16] “Transbronchial lung biopsy for the diagnosis of IgG4-related lung disease,” *Histopathology*, Jul. 2018.
- [17] “A genomic and clinicopathological study of non-small-cell lung cancers with discordant *ROS1* gene status by fluorescence *in-situ* hybridisation and immunohistochemical analysis,” *Histopathology*, Jul. 2018.
- [18] “GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4 α expression, and *KRAS* mutations,” *Histopathology*, Jul. 2018.
- [19] “Utility of Pathology Imagebase for standardisation of prostate cancer grading,” *Histopathology*, Jul. 2018.
- [20] “Gleason score assignment is the sole responsibility of the pathologist,” *Histopathology*, Jul. 2018.

Diagnostic Histopathology

- [1] “EBV-associated ulceration in an immunocompromised patient,” *Diagnostic Histopathol.*, Jul. 2018.
- [2] “Lymphoproliferative disorders and lymphoreticular malignancies in the setting of immunodeficiency,” *Diagnostic Histopathol.*, Jul. 2018.
- [3] “Diagnosis of NK and cytotoxic T-cell disorders: a review,” *Diagnostic Histopathol.*, Jul. 2018.
- [4] “Nodal T-cell lymphomas with a T-follicular helper cell phenotype,” *Diagnostic Histopathol.*, Jul. 2018.
- [5] “An update on high grade B-cell lymphoma,” *Diagnostic Histopathol.*, Jul. 2018.

MODERN PATHOLOGY

- [1] **“Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.”** *Mod. Pathol.*, Jun. 2018.
- [2] **“Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases.”** *Mod. Pathol.*, Jul. 2018.
- [3] **“Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency.”** *Mod. Pathol.*, Jul. 2018.
- [4] **“Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary.”** *Mod. Pathol.*, Jul. 2018.
- [5] **“Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association.”** *Mod. Pathol.*, Jul. 2018.
- [6] **“hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality.”** *Mod. Pathol.*, Jul. 2018.
- [7] **“Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus.”** *Mod. Pathol.*, Jul. 2018.
- [8] **“Lipoblastoma-like tumor of the vulva: a clinicopathologic, immunohistochemical, fluorescence in situ hybridization and genomic copy number profiling study of seven cases.”** *Mod. Pathol.*, Jul. 2018.
- [9] **“Role of columnar cell lesions in breast carcinogenesis: analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification.”** *Mod. Pathol.*, Jul. 2018.
- [10] **“PAX7 expression in sarcomas bearing the EWSR1-NFATC2 translocation.”** *Mod. Pathol.*, Jul. 2018.

Journal of Clinical Oncology®

An American Society of Clinical Oncology Journal

- [1] **“Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study,”** *J. Clin. Oncol.*, Sep. 2011.
- [2] **“Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial,”** *J. Clin. Oncol.*, Feb. 2016.
- [3] **“Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update,”** *J. Clin. Oncol.*, Jan. 2017.
- [4] **“American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care,”** *J. Clin. Oncol.*, Mar. 2012.
- [5] **“American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options,”** *J. Clin. Oncol.*, Aug. 2015.
- [6] **“Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline,”** *J. Clin. Oncol.*, Jun. 2018.
- [7] **“Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update,”** *J. Clin. Oncol.*, May 2018.
- [8] **“Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study,”** *J. Clin. Oncol.*, Jul. 2013.
- [9] **“Alcohol and Cancer: A Statement of the American Society of Clinical Oncology,”** *J. Clin. Oncol.*, Jan. 2018.
- [10] **“Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update,”** *J. Clin. Oncol.*, Oct. 2017.
- [11] **“New Agents, Emerging Late Effects, and the Development of Precision Survivorship,”** *J. Clin. Oncol.*, Jul. 2018.

- [12] **“Surveillance for Late Effects in Childhood Cancer Survivors,”** *J. Clin. Oncol.*, Jul. 2018.
- [13] **“Models of Care for Survivors of Childhood Cancer From Across the Globe: Advancing Survivorship Care in the Next Decade,”** *J. Clin. Oncol.*, Jul. 2018.
- [14] **“Premature Physiologic Aging as a Paradigm for Understanding Increased Risk of Adverse Health Across the Lifespan of Survivors of Childhood Cancer,”** *J. Clin. Oncol.*, Jul. 2018.
- [15] **“Psychological Symptoms, Social Outcomes, Socioeconomic Attainment, and Health Behaviors Among Survivors of Childhood Cancer: Current State of the Literature,”** *J. Clin. Oncol.*, Jul. 2018.
- [16] **“Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Research,”** *J. Clin. Oncol.*, Jul. 2018.
- [17] **“Financial Hardship and the Economic Effect of Childhood Cancer Survivorship,”** *J. Clin. Oncol.*, Jul. 2018.
- [18] **“Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review,”** *J. Clin. Oncol.*, Jul. 2018.
- [19] **“Endocrine Late Effects in Childhood Cancer Survivors,”** *J. Clin. Oncol.*, Jul. 2018.
- [20] **“Neurocognitive Outcomes and Interventions in Long-Term Survivors of Childhood Cancer,”** *J. Clin. Oncol.*, Jul. 2018.
- [21] **“Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review,”** *J. Clin. Oncol.*, Jul. 2018.
- [22] **“Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention,”** *J. Clin. Oncol.*, Jul. 2018.
- [23] **“Optimization of Health and Extension of Lifespan Through Childhood Cancer Survivorship Research,”** *J. Clin. Oncol.*, Jul. 2018.

JAMA Oncology

- [1] **“Immune-Related Adverse Events—A Novel Prediction of Nivolumab Efficacy?—Reply,”** *JAMA Oncol.*, Jul. 2018.
- [2] **“Incorrect Email Address for Corresponding Author,”** *JAMA Oncol.*, Jul. 2018.
- [3] **“Immune-Related Adverse Events—A Novel Prediction of Nivolumab Efficacy?,”** *JAMA Oncol.*, Jul. 2018.
- [4] **“Association of Statin Use With Overall and Cancer Survival—Reply,”** *JAMA Oncol.*, Jul. 2018.
- [5] **“Association of Statin Use With Overall and Cancer Survival,”** *JAMA Oncol.*, Jul. 2018.
- [6] **“Association of Statin Use With Overall and Cancer Survival,”** *JAMA Oncol.*, Jul. 2018.
- [7] **“Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia—Reply,”** *JAMA Oncol.*, Jul. 2018.
- [8] **“Improving the Propranolol Treatment of Melanoma—Reply,”** *JAMA Oncol.*, Jul. 2018.
- [9] **“Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than *BRC1* and *BRC2*—Reply,”** *JAMA Oncol.*, Jul. 2018.
- [10] **“Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia,”** *JAMA Oncol.*, Jul. 2018.

- [11] **“Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than *BRCA1* and *BRCA2*,”** *JAMA Oncol.*, Jul. 2018.
- [12] **“Improving the Propranolol Treatment of Melanoma,”** *JAMA Oncol.*, Jul. 2018.
- [13] **“When You Hear Hoofbeats, Look for Horses, Not Zebras—Reply,”** *JAMA Oncol.*, Jul. 2018.
- [14] **“When You Hear Hoofbeats, Look for Horses, Not Zebras,”** *JAMA Oncol.*, Jul. 2018.
- [15] **“Misclassification of Upper Tract Urothelial Carcinoma in Patients With Lynch Syndrome—Reply,”** *JAMA Oncol.*, Jul. 2018.
- [16] **“Misclassification of Upper Tract Urothelial Carcinoma in Patients With Lynch Syndrome,”** *JAMA Oncol.*, Jul. 2018.
- [17] **“Acceptance in the End of Life,”** *JAMA Oncol.*, Jul. 2018.
- [18] **“Biosimilars,”** *JAMA Oncol.*, Jul. 2018.
- [19] **“Characterizing an Ultra–High-Risk Subset of Patients With Hypopharynx and Larynx Cancer,”** *JAMA Oncol.*, Jul. 2018.
- [20] **“Smoking and Death From Prostate Cancer,”** *JAMA Oncol.*, Jul. 2018.
- [21] **“Reliably Quantifying Bone Metastases in Prostate Cancer—Are We Finally There?,”** *JAMA Oncol.*, Jul. 2018.
- [22] **“Is There Validity in Propensity Score–Matched Estimates of Adjuvant Chemotherapy Effects for Patients With Rectal Cancer?,”** *JAMA Oncol.*, Jul. 2018.
- [23] **“Thalidomide, Drug Safety, and Off-label Prescribing,”** *JAMA Oncol.*, Jul. 2018.
- [24] **“Addressing Financial Barriers to Enrollment in Clinical Trials,”** *JAMA Oncol.*, Jul. 2018.
- [25] **“US Public Perceptions About Cancer Care Provided by Smaller Hospitals Associated With Large Hospitals Recognized for Specializing in Cancer Care,”** *JAMA Oncol.*, Jul. 2018.
- [26] **“Pink Papules in a Patient With Salivary Duct Carcinoma,”** *JAMA Oncol.*, Jul. 2018.
- [27] **“Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality,”** *JAMA Oncol.*, Jul. 2018.
- [28] **“Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non–Small Cell Lung Cancer,”** *JAMA Oncol.*, Jul. 2018.
- [29] **“Association of Patient Sex With Chemotherapy-Related Toxic Effects,”** *JAMA Oncol.*, Jul. 2018.
- [30] **“Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography With Negative Results,”** *JAMA Oncol.*, Jul. 2018.
- [31] **“Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia,”** *JAMA Oncol.*, Jul. 2018.
- [32] **“Total Costs of Chimeric Antigen Receptor T - Cell Immunotherapy,”** *JAMA Oncol.*, Jul. 2018.
- [33] **“Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016,”** *JAMA Oncol.*, Jul. 2018.
- [34] **“Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With *RAS* and *BRAF* Mutational Status,”** *JAMA Oncol.*, Jul. 2018.
- [35] **“Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma,”** *JAMA Oncol.*, Jul. 2018.

- [36] “Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia,” *JAMA Oncol.*, Jul. 2018.
- [37] “Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer,” *JAMA Oncol.*, Jul. 2018.
- [38] “Delays in the Publication of Important Clinical Trial Findings in Oncology,” *JAMA Oncol.*, Jul. 2018.
- [39] “Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer,” *JAMA Oncol.*, Jul. 2018.
- [40] “Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer,” *JAMA Oncol.*, Jul. 2018.
- [41] “Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy,” *JAMA Oncol.*, Jul. 2018.
- [42] “Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer,” *JAMA Oncol.*, Jul. 2018.
- [43] “Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma,” *JAMA Oncol.*, Jul. 2018.
- [44] “Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection,” *JAMA Oncol.*, Jul. 2018.
- [45] “Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection,” *JAMA Oncol.*, Jul. 2018.

ANNALS OF ONCOLOGY

- [1] “Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab,” *Ann. Oncol.*, Jan. 2018.
- [2] “A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC),” *Ann. Oncol.*, Jan. 2018.
- [3] “Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?,” *Ann. Oncol.*, Jan. 2018.
- [4] “Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population,” *Ann. Oncol.*, Mar. 2018.
- [5] “Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanoma,” *Ann. Oncol.*, May 2018.
- [6] “Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells,” *Ann. Oncol.*, Apr. 2018.
- [7] “The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?,” *Ann. Oncol.*, May 2018.
- [8] “HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients,” *Ann. Oncol.*, Jun. 2018.
- [9] “The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients,” *Ann. Oncol.*, May 2018.

- [10] **“Industry corner: perspectives and controversies,”** *Ann. Oncol.*, Apr. 2018.
- [11] **“Representation of obese participants in obesity-related cancer randomized trials,”** *Ann. Oncol.*, Apr. 2018.
- [12] **“T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression,”** *Ann. Oncol.*, Apr. 2018.
- [13] **“Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma,”** *Ann. Oncol.*, Apr. 2018.
- [14] **“Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer,”** *Ann. Oncol.*, May 2018.
- [15] **“A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors,”** *Ann. Oncol.*, May 2018.
- [16] **“Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer,”** *Ann. Oncol.*, Apr. 2018.
- [17] **“Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts,”** *Ann. Oncol.*, May 2018.
- [18] **“Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy,”** *Ann. Oncol.*, May 2018.
- [19] **“Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial,”** *Ann. Oncol.*, Apr. 2018.
- [20] **“Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO,”** *Ann. Oncol.*, Apr. 2018.
- [21] **“Advances in the systemic treatment of melanoma brain metastases,”** *Ann. Oncol.*, May 2018.
- [22] **“Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis,”** *Ann. Oncol.*, Jun. 2018.
- [23] **“Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points,”** *Ann. Oncol.*, Jul. 2018.



THE AMERICAN JOURNAL OF
SURGICAL PATHOLOGY

- [1] **“The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [2] **“Poorly Differentiated Nonkeratinizing Squamous Cell Carcinoma of the Thymus: Clinicopathologic and Molecular Genetic Study of 25 Cases,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [3] **“Pyloric Gland Adenoma (PGA) of the Gallbladder: A Unique and Distinct Tumor from PGAs of the Stomach, Duodenum, and Pancreas,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [4] **“Frequent GNAQ and GNA14 Mutations in Hepatic Small Vessel Neoplasm,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [5] **“Molecular Profiling of Hyalinizing Clear Cell Carcinomas Revealed a Subset of Tumors Harboring a Novel EWSR1-CREM Fusion: Report of 3 Cases,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [6] **“Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum,”** *Am. J. Surg. Pathol.*, Jul. 2018.

- [7] **“Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [8] **“Human Herpes Virus 6 (HHV-6)-associated Lymphadenitis: Pitfalls in Diagnosis in Benign and Malignant Settings,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [9] **“Cutaneous Non-Neural Granular Cell Tumors Harbor Recurrent ALK Gene Fusions,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [10] **“Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [11] **“Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis?,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [12] **“Acquired Cystic Disease-associated Renal Cell Carcinoma (ACKD-RCC)-like Cysts,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [13] **“Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [14] **“Uterine PEComas: A Morphologic, Immunohistochemical, and Molecular Analysis of 32 Tumors,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [15] **“Loss of SATB2 Expression in Colorectal Carcinoma is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [16] **“Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN),”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [17] **“Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH: A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [18] **“Pulmonary Carcinomas With Mucinous and Neuroendocrine Differentiation: Expanding the Spectrum of Amphicrine Carcinomas,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [19] **“Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [20] **“ALK is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [21] **“PRAME Expression in Melanocytic Tumors,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [22] **“Epithelial Inclusions in Gallbladder Specimens Mimic Parasite Infection: Histologic and Molecular Examination of Reported *Cystoisopora belli* Infection in Gallbladders of Immunocompetent Patients,”** *Am. J. Surg. Pathol.*, Jul. 2018.
- [23] **“Central Nervous System-type Neuroepithelial Tumors and Tumor-like Proliferations Developing in the Gynecologic Tract and Pelvis: Clinicopathologic Analysis of 23 Cases,”** *Am. J. Surg. Pathol.*, Aug. 2018.
- [24] **“Treatment Effects Can Mimic Recurrent Extramammary Paget Disease in Perianal Skin,”** *Am. J. Surg. Pathol.*, Jul. 2018.



Leading the way in experimental and clinical research in hematology

- [1] **“Cuplike nuclear morphology in pediatric B-cell acute lymphoblastic leukemia,”** *Blood*, Jul. 2018.
- [2] **“Zhao Z, Sun Q, Sokoll LJ, et al. Eltrombopag mobilizes iron in patients with aplastic anemia. *Blood*. 2018;131(21):2399-2402.”** *Blood*, Jul. 2018.
- [3] **“Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. *Blood*. 2017;130(25):2709-2717.”** *Blood*, Jul. 2018.
- [4] **“NUT midline carcinoma with leukemic presentation mimicking CD34-positive acute leukemia,”** *Blood*, Jul. 2018.
- [5] **“Bim regulates the survival and suppressive capability of CD8⁺ FOXP3⁺ regulatory T cells during murine GVHD,”** *Blood*, Jul. 2018.
- [6] **“USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism,”** *Blood*, Jul. 2018.
- [7] **“The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?,”** *Blood*, Jul. 2018.
- [8] **“Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective,”** *Blood*, Jul. 2018.
- [9] **“Treatment strategies for adolescent and young adult patients with acute myeloid leukemia,”** *Blood*, Jul. 2018.
- [10] **“Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?,”** *Blood*, Jul. 2018.
- [11] **“A tale of two mantle cell lymphomas,”** *Blood*, Jul. 2018.
- [12] **“Normalizing hepcidin predicts *TMPRSS6* mutation status in patients with chronic iron deficiency,”** *Blood*, Jul. 2018.
- [13] **“A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome,”** *Blood*, Jul. 2018.
- [14] **“Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial,”** *Blood*, Jul. 2018.
- [15] **“Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL,”** *Blood*, Jul. 2018.
- [16] **“Hypoxia downregulates protein S expression,”** *Blood*, Jul. 2018.
- [17] **“Introduction to a review series on adolescent and young adult malignant hematology;,”** *Blood*, Jul. 2018.
- [18] **“Ambiguous lineage leukemia treatment,”** *Blood*, Jul. 2018.
- [19] **“Table of contents. *Blood*. 2018;131(18):ix-x.”** *Blood*, Jul. 2018.
- [20] **“Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response,”** *Blood*, Jul. 2018.

- [21] **“Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven,”** *Blood*, Jul. 2018.
- [22] **“Aberrant T-cell antigen expression in a plasma cell neoplasm,”** *Blood*, Jul. 2018.
- [23] **“International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia,”** *Blood*, Jul. 2018.
- [27] **“PI3K inhibitors and the search for the Holy Grail,”** *Blood*, Jul. 2018.
- [28] **“The cells are ambiguous, not the message,”** *Blood*, Jul. 2018.
- [29] **“Phase 1 study of the PI3K δ inhibitor INCB040093 \pm JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma,”** *Blood*, Jul. 2018.
- [33] **“Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas,”** *Blood*, Jul. 2018.
- [34] **“How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa,”** *Blood*, Jul. 2018.
- [36] **“Internuclear bridging outside of primary myelodysplasia and congenital dyserythropoietic anemia,”** *Blood*, Jul. 2018.
- [37] **“Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population,”** *Blood*, Jul. 2018.
- [40] **“FDG-PET in PMBCL: which heterogeneity?,”** *Blood*, Jul. 2018.
- [41] **“Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma,”** *Blood*, Jul. 2018.
- [45] **“Concurrent *JAK2* mutation and isolated del(5q) associated with marrow fibrosis and small hypo/monolobated megakaryocytes,”** *Blood*, Jul. 2018.
- [46] **“Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis,”** *Blood*, Jul. 2018.
- [47] **“T-cell prolymphocytic leukemia negative for surface CD3 and CD45,”** *Blood*, Jul. 2018.
- [48] **“The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma,”** *Blood*, Jul. 2018.
- [49] **“A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy,”** *Blood*, Jul. 2018.
- [50] **“Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil,”** *Blood*, Jul. 2018.
- [51] **“Getting to transplant in Hodgkin lymphoma: BVB,”** *Blood*, Jul. 2018.
- [52] **“How and when I do allogeneic transplant in CLL,”** *Blood*, Jul. 2018.
- [54] **“Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?,”** *Blood*, Jul. 2018.
- [55] **“The FLIPI nowadays: validation and modification,”** *Blood*, Jul. 2018.
- [56] **“Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma,”** *Blood*, Jul. 2018.



The NEW ENGLAND JOURNAL of MEDICINE

- [1] **“The Key Role of Epigenetics in Human Disease,”** *N. Engl. J. Med.*, Jul. 2018.
- [2] **“Calciphylaxis,”** *N. Engl. J. Med.*, Jul. 2018.
- [3] **“Duration of Adjuvant Chemotherapy for Stage III Colon Cancer,”** *N. Engl. J. Med.*, Jul. 2018.
- [4] **“Prehospital Damage-Control Resuscitation,”** *N. Engl. J. Med.*, Jul. 2018.
- [5] **“Pyoderma Gangrenosum in Ulcerative Colitis,”** *N. Engl. J. Med.*, Jul. 2018.
- [6] **“Update on Keratinocyte Carcinomas,”** *N. Engl. J. Med.*, Jul. 2018.
- [7] **“PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma,”** *N. Engl. J. Med.*, Jul. 2018.
- [8] **“Saving Thyroids — Overtreatment of Small Papillary Cancers,”** *N. Engl. J. Med.*, Jul. 2018.
- [9] **“Self-Insured Employers — The Payment-Reform Wild Card,”** *N. Engl. J. Med.*, Jul. 2018.
- [10] **“Protecting Mothers and Babies — A Delicate Balancing Act,”** *N. Engl. J. Med.*, Jul. 2018.
- [11] **“Clinical Examination of the Shoulder,”** *N. Engl. J. Med.*, Sep. 2016.
- [12] **“Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception,”** *N. Engl. J. Med.*, Jul. 2018.
- [13] **“Tickborne Diseases — Confronting a Growing Threat,”** *N. Engl. J. Med.*, Jul. 2018.
- [14] **“Crossing Borders,”** *N. Engl. J. Med.*, Jul. 2018.
- [15] **“The Republican War on Obamacare — What Has It Achieved?,”** *N. Engl. J. Med.*, Jul. 2018.